| dc.contributor.author | Fernández-González, Juan Francisco | |
| dc.contributor.author | García Pedraza, José Ángel | |
| dc.contributor.author | Terol-Úbeda, Anaïs Clara | |
| dc.contributor.author | Martín Calvo, María Luisa | |
| dc.contributor.author | Morán Benito, Asunción | |
| dc.contributor.author | García Domingo, Mónica | |
| dc.date.accessioned | 2025-02-14T13:13:06Z | |
| dc.date.available | 2025-02-14T13:13:06Z | |
| dc.date.issued | 2024-07 | |
| dc.identifier.citation | Fernández-González, J. F., García-Pedraza, J. Á., Terol-Úbeda, A. C., Martín, M. L., Morán, A., & García-Domingo, M. (2024). Chronic sarpogrelate treatment improves renal sympathetic hyperactivity in experimental diabetes. Biomedicine & Pharmacotherapy, 176, 116814.https://doi.org/10.1016/j.biopha.2024.116814 | es_ES |
| dc.identifier.issn | 0753-3322 | |
| dc.identifier.uri | http://hdl.handle.net/10366/163737 | |
| dc.description.abstract | [EN]Diabetes and derived complications, especially diabetic nephropathy and neuropathy annually cause great morbimortality worldwide. 5-hydroxytryptamine (5-HT) acts as a modulator of renal sympathetic input and vascular tone. In this line, 5-HT2 receptor blockade has been linked with reduced incidence and progression of diabetic microvascular alterations. In this work, we aimed to determine, in diabetic rats, whether 5-HT2 blockade ameliorates renal function and to characterize the serotonergic modulatory action on renal sympathetic neurotransmission. Diabetes was induced in male Wistar rats by alloxan administration (150 mg/kg, s.c.), and sarpogrelate (30 mg/kg·day, p.o.; 5-HT2 antagonist) was administered for 14 days (DM-S). Normoglycemic and diabetic (DM) animals were maintained as aged-matched controls. At 28th day, DM-S animals were anesthetized and prepared for the in situ autoperfusion of the kidney. Renal vasoconstrictor responses were induced electrically or by i.a. noradrenaline (NA) administration. The role of 5-HT and selective 5-HT agonist/antagonist were studied on these renal vasopressor responses. Sarpogrelate treatment decreased renal sympathetic-induced vasopressor responses, reduced renal hypertrophy and kidney damage markers increased in DM. Intraarterial 5-HT inhibited the sympathetic-induced renal vasoconstrictions, effect reproduced by 5-CT, AS-19, L-694,247 and LY 344864 (5-HT1/5/7, 5-HT7, 5-HT1D and 5-HT1F receptor agonists, respectively). Blocking 5-HT1D/1F/7 receptors completely abolished the 5-CT sympatho-inhibition. NA vasoconstrictions were not altered by any of the 5-HT agonists tested. Thus, in experimental diabetes, chronic sarpogrelate treatment reduces renal damage markers, kidney hypertrophy and renal sympathetic hyperactivity and modifies serotonergic modulation of renal sympathetic neurotransmission, causing a sympatho-inhibition by prejunctional 5-HT1D/1F and 5-HT7 activation. | es_ES |
| dc.format.mimetype | application/pdf | |
| dc.language.iso | eng | es_ES |
| dc.publisher | Elsevier | es_ES |
| dc.rights | Attribution-NoDerivatives 4.0 Internacional | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nd/4.0/ | * |
| dc.subject | 5-HT modulation | es_ES |
| dc.subject | diabetes | es_ES |
| dc.subject | nephropathy | es_ES |
| dc.subject | sarpogrelate | es_ES |
| dc.subject | sympathetic neurotransmission | es_ES |
| dc.subject | sympatholytic effect | es_ES |
| dc.subject.mesh | Serotonin | * |
| dc.subject.mesh | Serotonin 5-HT2 Receptor Antagonists | * |
| dc.subject.mesh | Diabetes Mellitus | * |
| dc.subject.mesh | Rats | * |
| dc.subject.mesh | Animals | * |
| dc.subject.mesh | Vasoconstriction | * |
| dc.subject.mesh | Kidney | * |
| dc.subject.mesh | Diabetic Nephropathies | * |
| dc.subject.mesh | Sympathetic Nervous System | * |
| dc.title | Chronic sarpogrelate treatment improves renal sympathetic hyperactivity in experimental diabetes. | es_ES |
| dc.type | info:eu-repo/semantics/article | es_ES |
| dc.relation.publishversion | https://doi.org/10.1016/j.biopha.2024.116814 | es_ES |
| dc.subject.unesco | 3209 Farmacología | es_ES |
| dc.identifier.doi | 10.1016/j.biopha.2024.116814 | |
| dc.relation.projectID | University of Salamanca (project number 18.K233 / 463AC01) | es_ES |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | es_ES |
| dc.identifier.pmid | 38820974 | |
| dc.identifier.essn | 1950-6007 | |
| dc.journal.title | Biomedicine and Pharmacotherapy | es_ES |
| dc.volume.number | 176 | es_ES |
| dc.page.initial | 116814 | es_ES |
| dc.type.hasVersion | info:eu-repo/semantics/publishedVersion | es_ES |
| dc.subject.decs | vasoconstricción | * |
| dc.subject.decs | antagonistas de receptores de serotonina 5-HT2 | * |
| dc.subject.decs | riñón | * |
| dc.subject.decs | animales | * |
| dc.subject.decs | serotonina | * |
| dc.subject.decs | ratas | * |
| dc.subject.decs | nefropatías diabéticas | * |
| dc.subject.decs | diabetes mellitus | * |
| dc.subject.decs | sistema nervioso simpático | * |
Stöbern
Gesamter BestandBereiche & SammlungenErscheinungsdatumAutorenSchlagwortenTitelnDiese SammlungErscheinungsdatumAutorenSchlagwortenTiteln
Mein Benutzerkonto
Statistiken
ENLACES Y ACCESOS
Derechos de autorPolíticasGuías de autoarchivoFAQAdhesión USAL a la Declaración de BerlínProtocolo de depósito, modificación y retirada de documentos y datosSolicitud de depósito, modificación y retirada de documentos y datos








